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New strategies for cholera control
Cholera remains a serious global public health problem, 
disproportionately aﬀ ecting poor individuals, causing 
illness and death for thousands of people each year. 
Cholera cases are on the rise, with 47% more cases 
reported to WHO in 2014 than in 2013.1 Innovative 
approaches to control the disease are urgently needed, 
and the study by Andrew Azman and colleagues in 
The Lancet Global Health2 contributes to growing 
evidence of the important part that oral cholera vaccine 
strategies have to play in this regard.
Cholera can have devastating consequences, especially 
in epidemic settings. Azman and colleagues’ study 
assesses the eﬀ ectiveness of a single dose of bivalent 
whole-cell oral cholera vaccine on epidemic cholera in 
Juba, South Sudan. Typically, this oral cholera vaccine 
is given in two doses 14 days apart, and studies have 
shown its eﬃ  cacy and eﬀ ectiveness with this dosing 
schedule.3–5 However, the use of one dose of vaccine for 
an outbreak response would reduce costs and double 
the number of people that could be served, which is 
especially important considering the global shortage of 
vaccine that is expected to last for the next few years. 
Faced with an emerging epidemic of cholera in South 
Sudan, limited vaccine supply, and some evidence that 
a single dose of vaccine might give suﬃ  cient protection 
to thwart an epidemic, local public health oﬃ  cials and 
the non-governmental organisation Médecins Sans 
Frontières decided to proceed with a single-dose public 
health oral cholera vaccine campaign in Juba. Public 
health activities and a research study took place hand 
in hand.
The study found that the adjusted single-dose vaccine 
eﬀ ectiveness was 87·3% (70·2–100·0) for reducing 
medically attended cholera for up to 2 months. This 
adds to existing evidence including a randomised 
study of a single-dose regimen from Bangladesh that 
found 40% direct eﬀ ectiveness for reducing all cholera, 
and 63% direct eﬀ ectiveness for reducing severely 
dehydrating cholera at 6 months.6 By contrast, Azman 
and colleagues used a case-cohort study design in an 
eﬀ ort to measure both the direct and indirect protection 
oﬀ ered by the vaccine (ie, herd protection), and 
measured eﬀ ectiveness in a shorter period. This design 
makes the study particularly interesting and pertinent to 
dilemmas in the approach to cholera outbreak control. 
Debate continues between water, sanitation, and 
hygiene (WASH) purists, who believe that investments 
in cholera vaccination campaigns are a distraction from 
the goal of universal access to water and sanitation, 
and a more progressive public health community that 
advocates for a combined approach to cholera control 
including vaccination and evidence-based WASH 
interventions. In this context, a study that helps us to 
measure the herd protection of an oral cholera vaccine 
strategy is key to understanding the population-level 
eﬀ ect and therefore the public health usefulness of oral 
cholera vaccine (beyond individual protection).
This study is also an excellent example of research in 
action. Resolving, as the researchers did, to be scientiﬁ c 
in the context of rapid decision making and the often 
chaotic environment of an epidemic response is not 
straightforward. The context of the study means that 
the results are particularly useful for understanding 
the intervention as it might happen in the real world, 
outside of a formal research setting. More studies 
like this are needed for us to understand the right 
approaches for use of cholera vaccine.
Armed with the results of this study, public health 
oﬃ  cials and implementing organisations in areas where 
cholera occurs with some frequency should consider the 
option of using a single-dose vaccination campaign as 
part of an emergency outbreak response. This should be 
coupled with good monitoring and evaluation activities 
to continue to add to our knowledge on the issue.
Importantly, the usefulness of single-dose oral 
cholera vaccine in cholera-naive populations cannot be 
presumed on the basis of this study, and the authors 
acknowledge this fact. The impetus now exists, though, 
to study the approach in cholera-naive populations. 
Further questions also emerge that remain to be 
answered. How long does the protective eﬀ ect of a 
single dose of this oral cholera vaccine last in cholera-
experienced populations such as Juba? Does a single-
dose pre-emptive campaign prevent epidemic outbreaks 
in susceptible groups such as displaced people? How 
well protected are subgroups such as young children? 
What complementary emergency WASH activities at 
household or community level should be combined 
with the single-dose approach to ensure durable control 
of cholera? Would a booster dose sometime after the 
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initial outbreak response contribute to longer-term 
cholera control? To answer these pragmatic questions, 
we require continued investment in the global stockpile 
of cholera vaccine, forward-thinking health oﬃ  cials, and 
continued assessment of the vaccine’s use.
When the right to universal access to safe water 
and sanitation is realised, the world will be a better, 
healthier place—this is not doubted. However, if Haiti 
is any example, the struggle to execute on water and 
sanitation ideals is real. Those challenges are related 
both to the availability of funding, and the ability to 
deliver WASH interventions in suﬃ  cient quantity and 
quality to interrupt transmission of cholera as a matter 
of urgency. While the 2016 rainy season brings a surge 
in cholera cases in Haiti, this study oﬀ ers one potential 
vaccination strategy to consider in outbreak responses 
going forward. We can only wonder what might have 
happened in Haiti if Azman and colleagues’ research 
had pre-dated the Haitian cholera outbreak—the largest 
ongoing cholera outbreak in the world, with more than 
10 000 deaths so far.7,8 Perhaps oﬃ  cials, public health 
experts, and vaccine manufacturers would have done 
innovative work together in the early days, and helped 
to avert a disaster.
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